Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Guillin

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Bulletin De L'Academie Nationale De Medecine|October 19, 2020
[What antipsychotic drugs will be in the next decade?]O Guillin
L'Encephale|February 28, 2002
[Confusion and delusions occurring during interferon-alpha treatment]N Kayser, H Louiz, O Guillin
L'Encephale|December 28, 2013
[Pharmacological treatments in patients with pervasive developmental disorders: A review]L Béhérec, G Quilici, A Rosier, et al.
L'Encephale|April 28, 2009
[Chlorpromazine-induced agranulocytosis: a case report]F Stephan, M-A Podlipski, J-M Kerleau, et al.
Nature|May 3, 2001
BDNF controls dopamine D3 receptor expression and triggers behavioural sensitizationO Guillin, J Diaz, P Carroll, et al.
CNS & Neurological Disorders Drug Targets|April 15, 2006
The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disordersP Sokoloff, J Diaz, B Le Foll, et al.
L'Encephale|February 24, 2001
[Validation of the French translation and factorial structure of the Tiffany and Drobes Smoking Urge Questionnaire]O Guillin, M O Krebs, M C Bourdel, et al.
European Archives of Psychiatry and Clinical Neuroscience|May 13, 2024
Effects of web-based adapted physical activity on hippocampal plasticity, cardiorespiratory fitness, symptoms, and cardiometabolic markers in patients with schizophrenia: a randomized, controlled studyE Leroux, M Tréhout, E Reboursiere, et al.
Molecular Psychiatry|October 14, 2000
Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophreniaM O Krebs, O Guillin, M C Bourdell, et al.
L'Encephale|December 3, 2017
[Validation of the French version of the self-evaluation of negative symptoms (SNS)]C Hervochon, V Bourgeois, M Rotharmel, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Bulletin De L'Academie Nationale De Medecine|October 19, 2020
[What antipsychotic drugs will be in the next decade?]O Guillin
L'Encephale|February 28, 2002
[Confusion and delusions occurring during interferon-alpha treatment]N Kayser, H Louiz, O Guillin
L'Encephale|December 28, 2013
[Pharmacological treatments in patients with pervasive developmental disorders: A review]L Béhérec, G Quilici, A Rosier, et al.
L'Encephale|April 28, 2009
[Chlorpromazine-induced agranulocytosis: a case report]F Stephan, M-A Podlipski, J-M Kerleau, et al.
Nature|May 3, 2001
BDNF controls dopamine D3 receptor expression and triggers behavioural sensitizationO Guillin, J Diaz, P Carroll, et al.
CNS & Neurological Disorders Drug Targets|April 15, 2006
The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disordersP Sokoloff, J Diaz, B Le Foll, et al.
L'Encephale|February 24, 2001
[Validation of the French translation and factorial structure of the Tiffany and Drobes Smoking Urge Questionnaire]O Guillin, M O Krebs, M C Bourdel, et al.
European Archives of Psychiatry and Clinical Neuroscience|May 13, 2024
Effects of web-based adapted physical activity on hippocampal plasticity, cardiorespiratory fitness, symptoms, and cardiometabolic markers in patients with schizophrenia: a randomized, controlled studyE Leroux, M Tréhout, E Reboursiere, et al.
Molecular Psychiatry|October 14, 2000
Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophreniaM O Krebs, O Guillin, M C Bourdell, et al.
L'Encephale|December 3, 2017
[Validation of the French version of the self-evaluation of negative symptoms (SNS)]C Hervochon, V Bourgeois, M Rotharmel, et al.
Pageof 2